Holen Sie sich die Stockscreener-App
33.13
1.97%
0.665
Schlusskurs vom Vortag:
$32.47
Offen:
$33
24-Stunden-Volumen:
6.50M
Relative Volume:
0.29
Marktkapitalisierung:
$7.54B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
48.02
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-3.50%
1M Leistung:
-8.81%
6M Leistung:
-30.24%
1J Leistung:
+31.39%
1-Tages-Spanne:
$32.05
$33.25
1-Wochen-Bereich:
$32.05
$34.75
52-Wochen-Spanne:
$23.97
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
33.13 | 7.39B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
125.51 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.66 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
492.08 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
The Biomarker Blood Testing Gold Rush Is Here - Athletech News
HIMS Stock On A Losing Spree: Here's Why - Forbes
Market Sentiment Sours for Hims & Hers Shares - AD HOC NEWS
Mixed options sentiment in Hims and Hers Health with shares down 2.47% - Yahoo Finance
Healthcare Stocks To ConsiderJanuary 1st - MarketBeat
HIMS Stock Falls -8.7% With A 7-day Losing Spree On Valuation Concerns - Trefis
How Hims & Hers Health Inc. Class A (HIMS) Affects Rotational Strategy Timing - Stock Traders Daily
Best Healthcare Stocks Worth WatchingDecember 28th - MarketBeat
Healthcare Stocks To Watch TodayDecember 31st - MarketBeat
Unpacking the Latest Options Trading Trends in Hims & Hers Health - Benzinga
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus - ts2.tech
Hims & Hers Faces Investor Scrutiny Amid Profitability Concerns - AD HOC NEWS
Hims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should Know - sharewise.com
Notable Tuesday Option Activity: Z, UPS, HIMS - Nasdaq
Best Healthcare Stocks To Watch TodayDecember 30th - MarketBeat
HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand - Yahoo Finance
Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses - AOL.com
Hims & Hers Health (HIMS) Fell Due to Increased Regulatory Challenges - Insider Monkey
Hims & Hers Health Stock (HIMS) Opinions on Canadian Market Expansion - Quiver Quantitative
Top 10 Most Shorted Stocks: Lucid, MARA, Hims and More - Benzinga
TEM vs. HIMS: Which Medical Info Systems Stock Offers Greater Upside - Finviz
Promising Healthcare Stocks To Keep An Eye OnDecember 26th - MarketBeat
Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar - ts2.tech
Returns Recap: Why hedge funds are buying Hims Hers Health Inc stockBuy Signal & Expert Approved Momentum Ideas - moha.gov.vn
Hims & Hers: A Growth Story Battling Market Skepticism - AD HOC NEWS
Carnegie Investment Counsel Acquires 61,560 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Top Healthcare Stocks To Follow TodayDecember 23rd - MarketBeat
How Do Investors Really Feel About Hims & Hers Health Inc? - Benzinga
Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Why Hims & Hers Health, Inc. (HIMS) Went Up On Wednesday? - MSN
Assessing Hims and Hers After Its 462% Multi Year Surge and Premium Valuation Multiple - Yahoo Finance
HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling? - Finviz
The Zacks Analyst Blog Highlights Hims & Hers Health, Biotricity and Privia Health - The Globe and Mail
Hims & Hers Hit A GLP-1 Speed Bump This Year — But Growth Is Just Cooling, Not Cracking - Stocktwits
Hims & Hers Health Stock (HIMS) Opinions on Recent Volatility and Expansion - Quiver Quantitative
Voya Investment Management LLC Buys 52,370 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Hims & Hers quietly scooped up nearly 300,000 square feet in East Valley - The Business Journals
New Albany gains $200M health care expansion, 400 new jobs - Yahoo
Oluyemi Okupe Sells 23,090 Shares of Hims & Hers Health (NYSE:HIMS) Stock - MarketBeat
3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to Run - The Globe and Mail
Hims & Hers Expands Subscription-Led Care as Platform Engagement Grows - The Globe and Mail
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
How Novo Nordisk Is Trying to Regain Its Weight-Loss Edge - Bloomberg.com
Texas Permanent School Fund Corp Invests $2.57 Million in Hims & Hers Health, Inc. $HIMS - MarketBeat
(HIMS) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Is Hims & Hers Health’s US$200 Million Ohio Bet Quietly Redefining Its Core Strategy (HIMS)? - Yahoo Finance
2 Top Stocks to Buy With $500 Right Now - Yahoo Finance
Key Financial Officer’s Major Stock Sale Raises Questions at Hims & Hers - AD HOC NEWS
Insider Sell: Michael Chi Sells 13,750 Shares of Hims & Hers Hea - GuruFocus
Michael Chi Sells 13,750 Shares of Hims & Hers Health (NYSE:HIMS) Stock - MarketBeat
Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells 7,054 Shares of Stock - MarketBeat
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.43%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):